Pfizer Inc
NYSE: PFE
$26.74
+$0.03 (+0.1%)
Closing Price on December 24, 2024
PFE Articles
The October 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
These four top pharmaceutical companies have longstanding franchises with huge sales and revenues, and their dividend-paying stocks look like outstanding choices for worried investors to consider...
Published:
Last Updated:
Pfizer, in collaboration with Bain Capital, announced the creation of Cerevel Therapeutics, a new biopharmaceutical company focused on developing drug candidates to treat disorders of the central...
Published:
Last Updated:
Apple shares dipped again last week, but the company managed to hold onto its rank as the top-performing Dow stock for the year to date. Shares are up nearly 30% in 2018.
Published:
Last Updated:
In 2017, 20 of the 30 stocks that comprise the Dow Jones Industrial Average posted double-digit, year-over-year share price gains. So far this year, only 9 currently show a double-digit gain.
Published:
Last Updated:
For the second consecutive trading day, all 30 Dow stocks closed lower Thursday. Exxon, Chevron, Pfizer, and McDonald's were the biggest losers.
Published:
Last Updated:
The September 28 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks decreased.
Published:
Last Updated:
Pfizer shares hit multiyear highs and nearly an all-time in Monday’s session after the pharma giant announced a succession plan for its CEO.
Published:
Last Updated:
The September 14 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Last Updated:
The August 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Last Updated:
Here 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and U.S. Food and Drug Administration (FDA) updates in September.
Published:
Last Updated:
Pfizer shares slipped on Monday despite the company posting positive results from a late-stage tafamidis trial.
Published:
Last Updated:
The August 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks was mixed.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Thursday include Aetna, Analog Devices, Lowe's, Merck, Pfizer, Plug Power, Qualcomm and Target.
Published:
Big Pharma is looking good for investors in the second half of 2018. That's the message from the research team at Bank of America Merrill Lynch.
Published:
Last Updated: